JHEP Reports

JHEP Reports

CTAT methods

Tables for a "<u>C</u>omplete, <u>T</u>ransparent, <u>A</u>ccurate and <u>T</u>imely account" (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as 'Supplementary CTAT Table'
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

Name	Citation	Supplier	Cat no.	Clone no.
CD14-APC- eFluor780		Thermo Fisher Scientific	47-0149-42	61D3
CD16-PeCF594		BD Biosciences	562293	3G8
HLA-DR eFluor450		Thermo Fisher Scientific	48-9952-42	L243
CD66b-FITC		BD Biosciences	555724	G10F5
CD3-PE		Thermo Fisher Scientific	12-0037-42	ОКТ3
CD19-PE		Thermo Fisher Scientific	12-0199-42	HIB19
CD56-PE		Thermo Fisher Scientific	12-0567-42	CMSSB
CD68-PE-Cy7		Thermo Fisher Scientific	25-0689-42	Y1/82A
CD163-APC		Thermo Fisher Scientific	17-1639-42	GHI/61
CD206-PerCP- eFluor710		Thermo Fisher Scientific	46-2069-42	19.2
TGR-5-PE		R&D systems	FAB4286P	409522
TGR-5, purified		LifeSpan Biosciences, Inc.	LS-A1936-50	Rabbit polyclonal

1.1 Antibodies

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
N/A					

1.3 Organisms

JHEP Reports

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
N/A						

1.4 Sequence based reagents

Name	Sequence	Supplier
N/A		

1.5 Biological samples

Description	Source	Identifier	
Blood	QEHB	2003/242	
Liver	QEHB	06/Q2702/61	

See Text for human sample details.

1.6 Deposited data

Name of repository	Identifier	Link
N/A		

1.7 Software

Software name	Manufacturer	Version
GraphPad Prism 8	GraphPad Software, Inc.	8.0.0
Image J	NIH	1.48
FlowJo	FlowJo LLC	10.0.8

1.8 Other (e.g. drugs, proteins, vectors etc.)

INT-747	Abcam	ab144246
INT-777	Cambridge Bioscience	CAY17678-1mg
Recombinant human IL-4	PeproTech	200-04B-20µg
Recombinant human IFN- ^y	PeproTech	300-02B-100µg
Recombinant human MCSF	PeproTech	300-25B-10µg
Recombinant human GMCSF	PeproTech	300-03B-20µg

1.9 Please provide the details of the corresponding methods author for the manuscript:

N/A		

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

N/A